The use of buspirone in primary care

Journal of Psychosocial Nursing and Mental Health Services

Volumn 40, Issue 7, 2002, Pages 34-41

  Khouzam, Hani Raoul ^b   Emes, Robert ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Central California Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE;

ARTICLE; HUMAN; PRIMARY HEALTH CARE;

ANTI-ANXIETY AGENTS; BENZODIAZEPINES; BUSPIRONE; HUMANS; PRIMARY HEALTH CARE;

EID: 0036632048     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. th ed.). Washington, DC: Author.
2. Ballenger, J.C. (2001). Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. Journal of Clinical Psychiatry, 62(Suppl. 19), 11-19.
3. Barnes, N.M., & Sharp, T. (1999). A review of central 5-HT receptors and their function. Neuropharmacology, 38, 1083-1152.
4. Barros, M., Mello, E.L. Jr., Muston, J.P., & Tomaz, C. (2001). Behavioral effects of buspirone in the marmoset employing a predator confrontation test of fear and anxiety. Pharmacology Biochemistry and Behavior, 68, 255-262.
5. Bhandary, A.N., & Masand, P.S. (1997). Buspirone in the management of disruptive behaviors due to Huntington s disease and other neurological disorders. Psychosomatics, 38, 389-391.
6. Bostwick, J.M., & Jaffe, M.S. (1999). Buspirone as an antidote to SSRI-induced bruxism in four cases. Journal of Clinical Psychiatry, 60, 857-860.
7. Brawman-Mintzer, O. (2001). Pharmacologic treatment of generalized anxiety disorder. Psychiatric Clinics of North America, 24, 119-137.
8. Buitelaar, J.K., van der Gaag, R., & van der Hoeven, J. (1998). Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: Results of an open-label study. Journal of Clinical Psychiatry, 59, 56-59.
9. Carrey, N.J., Wiggins, D.M., & Milin, R.P. (1996). Pharmacological treatment of psychiatric disorders in children and adolescents: Focus on guidelines for the primary care practitioner. Drugs, 51, 750-759.
10. Doraiswamy, P.M. (2001). Contemporary management of comorbid anxiety and depression in geriatric patients. Journal of Clinical Psychiatry, 62(Suppl. 12), 30-35.
11. Farid, P., & Abate, M.A. (1998). Buspirone for smoking cessation. Annals of Pharmacotherapy, 32, 1362-1364.
12. Khouzam, H.R. (1999). Obsessive-compulsive disorder, what to do if you recognize baffling behavior. Postgraduate Medicine, 106, 133-141, 161.
13. Khouzam, H.R. (2000). The antidepressant nefazodone: A review of its pharmacology, clinical efficacy, adverse effects, dosage and administration. Journal of Psychosocial Nursing and Mental Health Services, 38(8), 20-25.
14. Khouzam, H.R., & Donnelly, N.J. (2001). Posttraumatic stress disorder, safe, effective management in the primary care setting. Postgraduate Medicine, 110(5), 60-78.
15. Levine, A.M. (1988). Buspirone and agitation in head injury. Brain Injury, 2, 165-167.
16. Lou, J.-S., Goldfarb, L., McShane, L., Gatev, P., & Hallett, M. (1995). Use of buspirone for treatment of cerebellar ataxia. Archives of Neurology, 52, 982-988.
17. Mahmood, I., & Sahajwalla, C. (1999). Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clinical Pharmacokinetics, 36, 277-287.
18. Moss, L.E., Neppe, V.M., & Drevets, W.C. (1993). Buspirone in the treatment of tardive dyskinesia. Journal of Clinical Psychopharmacology, 13, 204-209.
19. Myrick, M., Brady, K.T., & Malcolm, R. (2001). New developments in the pharmacotherapy of alcohol dependence. American Journal on Addictions, 10(Suppl.), 3-15.
20. Pascual, J., & Bernico, J. (1998). Buspirone in primary headaches. Acta Psychiatrica Scandinavia, 97, 142.
21. Rao, V., Lutchmansingh, P., & Poland, R.E. (2000). Contribution of development to buspirone effects on REM sleep: A preliminary report. Neuropsychopharmacology, 22, 440-446.
22. Reesal, R.T. (1999). Which medications should be prescribed to treat generalized anxiety disorder (GAD)? Journal of Psychiatry Neurosciences, 24, 80.
23. Rush, A.J., Batey, S.R., Donahue, R.M., Ascher, J.A., Carmody, T.J., & Metz, A. (2001). Does pretreatment anxiety predict response to either bupropion SR or sertraline? Journal of Affective Disorder, 64, 81-87.
24. Sakr, A., & Andheria, M. (2001). Pharmacokinetics of buspirone extended-release tablets: a single-dose study. Journal of Clinical Pharmacology, 41, 783-789.
25. Salzman, C. (2001). Treatment of the agitation of late-life psychosis and Alzheimers disease. European Psychiatry, 16(Suppl. 1), 25-28.
26. Sharma, A., Oyebode, F., Kendall, M.J., & Jones, D.A. (2001). Recovery from chronic fatigue syndrome associated with changes in neuroendocrine function. Journal of the Royal Society of Medicine, 94, 26-27.
27. Sramek, J.J., Frackiewicz, E.J., & Cutler, N.R. (1997). Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety. Clinical Therapeutics, 19, 598-606.
28. U.S. Department of Health and Human Services. (2000). Report of a surgeon generals working meeting on the integration of mental health services and primary care health care. Rockville, MD: Author.
29. Velesa, J.F., & Riddle, M.A. (2000). Pharmacologic treatment of anxiety disorders in children and adolescents. Child and Adolescent Psychiatric Clinics of North America, 9, 119-133.
30. Younkers, K.A. (1997). Anxiety symptoms and anxiety disorders: How are they related to premenstrual disorders. Journal of Clinical Psychiatry, 58(Suppl. 3), 62-67.
31. Zajecka, J. (2001). Strategies for the treatment of antidepressant related sexual dysfunction. Journal of Clinical Psychiatry, 62(Suppl. 3), 35-43.